Home › Solutions › Medical Devices › Brazil › Clinical evaluation
Clinical evidence · Brazil
ANVISA expects the indications, performance and safety of a medical device to be supported by clinical evidence. We prepare and update the clinical evaluation for your Brazilian file, building on what you already have for the EU or the US.

Is this for you?
What you get
A clinical evaluation structured for the ANVISA dossier.

The main points behind the clinical part of your Brazilian file. How they apply depends on the device.
How it works
Questions, answered
Rules cited on this page: RDC 848/2024 · RDC 751/2022 · RDC 837/2023 · IN 290/2024 · ANVISA Guide 31/2020 · ISO 14155
Yes, as a starting point. Your EU or FDA data can support the Brazilian evaluation, adapted to what ANVISA expects. We map your report to the Brazilian dossier and add what is missing, such as the indications and labelling declared in Brazil. For some higher-risk devices already authorised in certain markets, ANVISA rules allow the foreign authority’s assessment to be considered; we check whether your device can use this.
The clinical evaluation rules apply to all classes, but what is submitted differs. For notified devices, the documentation usually stays with the holder and is presented if ANVISA asks for it. For registered devices, a clinical evidence summary is part of the dossier.
When existing data are not enough to support the claims. Studies run in Brazil follow ANVISA and ethics committee procedures, which vary with the device and the study. We assess your case and help you plan the route.
Yes. ANVISA guidance describes the literature search, the use of comparable devices and the structure of the report. We apply it together with the current rules.
Our Clinical Evidence & Product Safety specialists, together with the regulatory team that prepares the rest of your ANVISA dossier.